Table 1 EORTC 1999 Criteria for FDG response (abridged)

1

Assessment at baseline just before and response at 1–2 weeks after end of chemotherapy cycle

2

Progressive disease (PMD) FDG SUV >25% within tumour RO1 of baseline

3

Stable disease (SMD) FDG SUV <25% ≥15%

4

Partial response (PMR) FDG SUV decrease of 15–25% after one cycle of chemotherapy or decrease over 25% for more than one cycle

5

Complete response (CMR) FDG SUV shows complete resolution within the baseline tumour RO1

6

Patlak kinetic approach is preferred. Reproducibility of FDG SUV is required.